Cochrane · systematic review · CD005642
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
Hauser, G, Awad, T, Thorlund, K, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
Population: patients with chronic hepatitis C.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Deaths during and after the treatment Peginterferon alpha‐2a vs peginterferon alpha‐2b | RR 1.97 [0.64, 6.08] | 1 study · 3070 participants | Very low Downgraded: risk of bias, imprecision |
Liver‐related morbidity Number of events Peginterferon alpha‐2a vs peginterferon alpha‐2b | RR 3 [0.7, 12.93] | 1 study · 36 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Number of events Peginterferon alpha‐2a vs peginterferon alpha‐2b | RR 1.12 [0.95, 1.3] | 4 studies · 3900 participants | Low Downgraded: imprecision |
Adverse events leading to treatment discontinuation Number of events Peginterferon alpha‐2a vs peginterferon alpha‐2b | RR 0.84 [0.57, 1.22] | 12 studies · 5340 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
All other (non‐serious) adverse events Peginterferon alpha‐2a vs peginterferon alpha‐2b | no estimate extracted | 9 studies · 4981 participants | Very low Downgraded: imprecision, inconsistency |
Quality of life SF 36 and CLDQ Peginterferon alpha‐2a vs peginterferon alpha‐2b | no estimate extracted | 1 study · 434 participants | Very low Downgraded: imprecision |
Sustained virological response Absence of viraemia 24 weeks after the treatment Peginterferon alpha‐2a vs peginterferon alpha‐2b | RR 1.12 [1.06, 1.18] | 12 studies · 5013 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |